These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11728244)

  • 1. Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure.
    Palkhiwala SA; Yu A; Frishman WH
    Heart Dis; 2000; 2(1):83-92. PubMed ID: 11728244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension.
    Yu A; Frishman WH
    J Clin Pharmacol; 1996 Feb; 36(2):98-111. PubMed ID: 8852385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
    Van Zwieten PA; Peters SL
    Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.
    Ernsberger P; Haxhiu MA; Graff LM; Collins LA; Dreshaj I; Grove DL; Graves ME; Schäfer SG; Christen MO
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():27-41. PubMed ID: 8068578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.
    Bousquet P; Feldman J
    Drugs; 1999 Nov; 58(5):799-812. PubMed ID: 10595861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
    van Zwieten PA
    Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
    Reid JL; Panfilov V; MacPhee G; Elliott HL
    Ann N Y Acad Sci; 1995 Jul; 763():673-8. PubMed ID: 7677387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From alpha and beta to I1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment.
    van Zwieten PA
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S5-10. PubMed ID: 8872294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Imidazol receptor agonists--new possibilities for treating hypertension].
    Nowicki M; Wiecek A; Chudek J
    Postepy Hig Med Dosw; 1995; 49(5):631-43. PubMed ID: 8677226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the antihypertensive efficacy of and tolerance to 2 imidazoline receptor agonists: moxonidine and rilmenidine in monotherapy].
    Camilleri G; Portal B; Quiniou G; Clerson P
    Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):169-74. PubMed ID: 12555509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine.
    van Zwieten PA
    J Hypertens; 1997 Feb; 15(2):117-25. PubMed ID: 9469786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renaissance of centrally acting antihypertensive drugs.
    van Zwieten PA
    J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxonidine: a review of safety and tolerability after seven years of clinical experience.
    Schachter M
    J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-dependent inhibition of neuronal c-jun in the brainstem elicited by imidazoline I1 receptor activation: role in rilmenidine-evoked hypotension.
    Wang X; Li G; Abdel-Rahman AA
    Eur J Pharmacol; 2005 May; 514(2-3):191-9. PubMed ID: 15910806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imidazole receptor agonists--a new advance in the treatment of hypertension?].
    Spinar J; Vítovec J
    Vnitr Lek; 2000 Feb; 46(2):122-5. PubMed ID: 11048538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New, modern, centrally active antihypertensive agents in the treatment of essential hypertension].
    Sevcík J; Masek K
    Cas Lek Cesk; 1999 Jun; 138(12):359-62. PubMed ID: 10566202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.